Roivant Sciences Ltd (ROIV) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Roivant Sciences Ltd stock (ROIV) is currently trading at $27.36. Roivant Sciences Ltd PS ratio (Price-to-Sales) is 1444.85. Analyst consensus price target for ROIV is $33.25. WallStSmart rates ROIV as Sell.
- ROIV PE ratio analysis and historical PE chart
- ROIV PS ratio (Price-to-Sales) history and trend
- ROIV intrinsic value — DCF, Graham Number, EPV models
- ROIV stock price prediction 2025 2026 2027 2028 2029 2030
- ROIV fair value vs current price
- ROIV insider transactions and insider buying
- Is ROIV undervalued or overvalued?
- Roivant Sciences Ltd financial analysis — revenue, earnings, cash flow
- ROIV Piotroski F-Score and Altman Z-Score
- ROIV analyst price target and Smart Rating
Roivant Sciences
📊 No data available
Try selecting a different time range
Smart Analysis
Roivant Sciences Ltd (ROIV) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Roivant Sciences Ltd (ROIV) Key Strengths (2)
73.13% of shares held by major funds and institutions
Large-cap company with substantial market presence
Supporting Valuation Data
Roivant Sciences Ltd (ROIV) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -77.80%, a shrinking business
Earnings declining -96.10%, profits shrinking
Very expensive at 1444.8x annual revenue
Premium pricing at 4.6x book value
Supporting Valuation Data
Roivant Sciences Ltd (ROIV) Detailed Analysis Report
Overall Assessment
This company scores 22/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 9.5/10) while 6 fall into concern territory (avg 1.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Market Cap.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (1444.85), Price/Book (4.64) suggest expensive pricing. Growth concerns include Revenue Growth at -77.80%, EPS Growth at -96.10%, which may limit upside. Profitability pressure is visible in Return on Equity at -19.10%, Operating Margin at -16965.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -19.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -77.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ROIV Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ROIV's Price-to-Sales ratio of 1444.85x trades 271% above its historical average of 389.86x (87th percentile), historically expensive. The current valuation is 10% below its historical high of 1598.09x set in Mar 2026, and 3132% above its historical low of 44.7x in Sep 2022. Over the past 12 months, the PS ratio has expanded from ~245.9x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Roivant Sciences Ltd (ROIV) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Roivant Sciences Ltd operates as a stable business with moderate growth and solid fundamentals. Revenue reached 13M with 78% decline year-over-year.
Key Findings
Debt-to-equity ratio of 0.05 indicates a conservative balance sheet with 1.5B in cash.
Spending 1243% of revenue (165M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 78% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -201M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Roivant Sciences Ltd.
Bottom Line
Roivant Sciences Ltd offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(54 last 3 months)
| Insider | Type | Shares |
|---|---|---|
EPPERLY, MELISSA B, Director | Sell | -41,861 |
Data sourced from SEC Form 4 filings
Last updated: 10:05:48 AM
About Roivant Sciences Ltd(ROIV)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Roivant Sciences Ltd (ROIV) is a pioneering biopharmaceutical company focused on transforming the way therapies are developed and commercialized, utilizing a distinctive model that leverages proprietary technologies. With a diverse pipeline addressing critical unmet needs in neurology, immunology, and rare diseases, Roivant aims to streamline the drug development process, thereby reducing time and costs associated with bringing new therapies to market. The company's strong leadership team and strategic partnerships further enhance its potential to disrupt the healthcare landscape, creating significant value for investors while improving patient outcomes.